

**Amendments to the Claims:**


This listing of the claims will replace all prior versions and listing of claims in the subject application.

Please amend claims 15, 16, 18 and 19 as shown.

1-13. (canceled)

14. (previously presented): A method for reducing blood cholesterol levels in a mammal suffering from hypercholesterolemia, comprising

administering to the mammal an effective amount of a composition comprising a compound of the following formula:



wherein

R1 = H or C<sub>1</sub>-C<sub>6</sub> alkyl;

R2 = H or C<sub>1</sub>-C<sub>3</sub> alkyl-X where X = H, OH, Cl, Br, I or F;

R3 = H or C<sub>1</sub>-C<sub>3</sub> alkyl;

R4 = H or C<sub>1</sub>-C<sub>3</sub> alkyl;

Y1 = CO<sub>2</sub>H, NH<sub>2</sub>SO<sub>2</sub>CF<sub>3</sub>, SO<sub>3</sub>H, PO<sub>3</sub>H<sub>2</sub>, OSO<sub>3</sub>H, CF<sub>3</sub> or F; and

Z1 = H or OH


or a pharmaceutically acceptable salt thereof.

15. (currently amended): The method according to claim 14, wherein the cholesterol levels are reduced in the sera of the blood.

16. (currently amended): The method according to claim 14, wherein the cholesterol levels are reduced in the plasma of the blood.

17. (previously presented): A method for reducing blood glucose levels in a mammal suffering from diabetes, comprising

administering to the mammal an effective amount of a composition comprising a compound of the following formula:



wherein

R1 = H or C<sub>1</sub>-C<sub>6</sub> alkyl;

R2 = H or C<sub>1</sub>-C<sub>3</sub> alkyl-X where X = H, OH, Cl, Br, I or F;

R3 = H or C<sub>1</sub>-C<sub>3</sub> alkyl;

R4 = H or C<sub>1</sub>-C<sub>3</sub> alkyl;

Y1 = CO<sub>2</sub>H, NHSO<sub>2</sub>CF<sub>3</sub>, SO<sub>3</sub>H, PO<sub>3</sub>H<sub>2</sub>, OSO<sub>3</sub>H, CF<sub>3</sub> or F; and

Z1 = H or OH

or a pharmaceutically acceptable salt thereof.

18. (currently amended): The method according to claim 17, wherein the glucose levels are reduced in the sera of the blood.

19. (currently amended): The method according to claim 17, wherein the glucose levels are reduced in the plasma of the blood.

20. (previously presented): The method according to claim 14 or claim 17, wherein the composition is administered in an amount of from about 0.01 mg/kg of body weight/day to about 100 mg/kg of body weight/day.

21. (previously presented): The method according to claim 20, wherein the composition is administered in an amount of from about 0.1 mg/kg of body weight/day to about 25 mg/kg of body weight/day.


22. (previously presented): The method according to claim 14 or claim 17, wherein the composition is administered transdermally, intramuscularly, intravenously, subcutaneously, intranasally, topically or orally.

23. (previously presented): The method according to claim 22, wherein the composition is administered subcutaneously or intravenously.

24. (previously presented): The method according to claim 14 or claim 17, further comprising a pharmaceutically acceptable carrier or excipient.

25. (previously presented): The method according to claim 14 or claim 17, wherein the mammal is a human.

26. (previously presented): The method according to claim 14, wherein the compound is




or a pharmaceutically acceptable salt thereof.

27. (previously presented): The method according to claim 26, wherein the hypercholesterolemia is associated with obesity.

28. (previously presented): The method according to claim 26, further comprising a pharmaceutically acceptable carrier or excipient.

29. (previously presented): The method according to claim 17, wherein the compound is



or a pharmaceutically acceptable salt thereof.

30. (previously presented): The method according to claim 29, further comprising a pharmaceutically acceptable carrier or excipient.